These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Antiarrhythmic therapy in patients with heart failure]. Faber TS, Zehender M. Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993 [Abstract] [Full Text] [Related]
3. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J. Am J Cardiol; 2003 Mar 20; 91(6A):15D-26D. PubMed ID: 12670638 [Abstract] [Full Text] [Related]
5. Dofetilide: a new class III antiarrhythmic agent. Roukoz H, Saliba W. Expert Rev Cardiovasc Ther; 2007 Jan 20; 5(1):9-19. PubMed ID: 17187453 [Abstract] [Full Text] [Related]
7. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. McClellan KJ, Markham A. Drugs; 1999 Dec 20; 58(6):1043-59. PubMed ID: 10651390 [Abstract] [Full Text] [Related]
8. Current treatment recommendations in antiarrhythmic therapy. Van Gelder IC, Brügemann J, Crijns HJ. Drugs; 1998 Mar 20; 55(3):331-46. PubMed ID: 9530541 [Abstract] [Full Text] [Related]
9. Arrhythmias in the intensive care patient. Trappe HJ, Brandts B, Weismueller P. Curr Opin Crit Care; 2003 Oct 20; 9(5):345-55. PubMed ID: 14508146 [Abstract] [Full Text] [Related]
10. Dofetilide: a new class III antiarrhythmic agent. Al-Dashti R, Sami M. Can J Cardiol; 2001 Jan 20; 17(1):63-7. PubMed ID: 11173316 [Abstract] [Full Text] [Related]
11. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. Singh BN, Wadhani N. J Cardiovasc Pharmacol Ther; 2004 Sep 20; 9 Suppl 1():S85-97. PubMed ID: 15378133 [Abstract] [Full Text] [Related]
12. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. Singh BN. J Cardiovasc Electrophysiol; 1999 Feb 20; 10(2):283-301. PubMed ID: 10090235 [Abstract] [Full Text] [Related]
13. The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Singh BN. Am J Cardiol; 1996 Aug 29; 78(4A):17-27. PubMed ID: 8780325 [Abstract] [Full Text] [Related]
14. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. Riera AR, Uchida AH, Ferreira C, Ferreira Filho C, Schapachnik E, Dubner S, Zhang L, Moffa PJ. Cardiol J; 2008 Aug 29; 15(3):209-19. PubMed ID: 18651412 [Abstract] [Full Text] [Related]
16. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. N Engl J Med; 1999 Sep 16; 341(12):857-65. PubMed ID: 10486417 [Abstract] [Full Text] [Related]
17. [Therapy of atrial fibrillation with class III anti-arrhythmia agents]. Follath F, Candinas R, Frielingsdorf J. Herz; 1993 Feb 16; 18(1):20-6. PubMed ID: 8454249 [Abstract] [Full Text] [Related]
19. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Howard PA. Ann Pharmacother; 1999 Jan 16; 33(1):38-47. PubMed ID: 9972384 [Abstract] [Full Text] [Related]